271 related articles for article (PubMed ID: 32420695)
1. A randomized, double-blind, vehicle-controlled clinical study of hair regeneration using adipose-derived stem cell constituent extract in androgenetic alopecia.
Tak YJ; Lee SY; Cho AR; Kim YS
Stem Cells Transl Med; 2020 Aug; 9(8):839-849. PubMed ID: 32420695
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Conditioned Media From Human Adipocyte-Derived Mesenchymal Stem Cells on Androgenetic Alopecia After Nonablative Fractional Laser Treatment.
Lee YI; Kim J; Kim J; Park S; Lee JH
Dermatol Surg; 2020 Dec; 46(12):1698-1704. PubMed ID: 32769526
[TBL] [Abstract][Full Text] [Related]
3. Combination of adipose-derived stem cell conditioned media and minoxidil for hair regrowth in male androgenetic alopecia: a randomized, double-blind clinical trial.
Legiawati L; Suseno LS; Sitohang IBS; Yusharyahya SN; Pawitan JA; Liem IK; Kurniawati T; Ardelia A; Paramastri K
Stem Cell Res Ther; 2023 Aug; 14(1):210. PubMed ID: 37605227
[TBL] [Abstract][Full Text] [Related]
4. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.
Olsen EA; Dunlap FE; Funicella T; Koperski JA; Swinehart JM; Tschen EH; Trancik RJ
J Am Acad Dermatol; 2002 Sep; 47(3):377-85. PubMed ID: 12196747
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo-controlled, double-blind, noninferiority study.
Blume-Peytavi U; Issiakhem Z; Gautier S; Kottner J; Wigger-Alberti W; Fischer T; Hoffmann R; Tonner F; Bouroubi A; Voisard JJ
J Cosmet Dermatol; 2019 Feb; 18(1):215-220. PubMed ID: 29659116
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of a Low-Level Light Therapy for Androgenetic Alopecia: A 24-Week, Randomized, Double-Blind, Self-Comparison, Sham Device-Controlled Trial.
Mai-Yi Fan S; Cheng YP; Lee MY; Lin SJ; Chiu HY
Dermatol Surg; 2018 Nov; 44(11):1411-1420. PubMed ID: 29957664
[TBL] [Abstract][Full Text] [Related]
7. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.
Lucky AW; Piacquadio DJ; Ditre CM; Dunlap F; Kantor I; Pandya AG; Savin RC; Tharp MD
J Am Acad Dermatol; 2004 Apr; 50(4):541-53. PubMed ID: 15034503
[TBL] [Abstract][Full Text] [Related]
8. Low-level laser therapy for the treatment of androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device-controlled trial.
Suchonwanit P; Chalermroj N; Khunkhet S
Lasers Med Sci; 2019 Aug; 34(6):1107-1114. PubMed ID: 30569416
[TBL] [Abstract][Full Text] [Related]
9. Sequential Scalp Assessment in Hair Regeneration Therapy Using an Adipose-Derived Stem Cell-Conditioned Medium.
Narita K; Fukuoka H; Sekiyama T; Suga H; Harii K
Dermatol Surg; 2020 Jun; 46(6):819-825. PubMed ID: 31490301
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a novel herbal solution for the treatment of androgenetic alopecia and comparison with 5% minoxidil: A double-blind, randomized controlled trial study.
Masoud F; Alamdari HA; Asnaashari S; Shokri J; Javadzadeh Y
Dermatol Ther; 2020 Nov; 33(6):e14467. PubMed ID: 33112463
[TBL] [Abstract][Full Text] [Related]
11. Topical valproic acid increases the hair count in male patients with androgenetic alopecia: a randomized, comparative, clinical feasibility study using phototrichogram analysis.
Jo SJ; Shin H; Park YW; Paik SH; Park WS; Jeong YS; Shin HJ; Kwon O
J Dermatol; 2014 Apr; 41(4):285-91. PubMed ID: 24533507
[TBL] [Abstract][Full Text] [Related]
12. Growth factor concentrations in platelet-rich plasma for androgenetic alopecia: An intra-subject, randomized, blinded, placebo-controlled, pilot study.
Siah TW; Guo H; Chu T; Santos L; Nakamura H; Leung G; Shapiro J; McElwee KJ
Exp Dermatol; 2020 Mar; 29(3):334-340. PubMed ID: 31984508
[TBL] [Abstract][Full Text] [Related]
13. Reduction of telogen rate and increase of hair density in androgenetic alopecia by a cosmetic product: Results of a randomized, prospective, vehicle-controlled double-blind study in men.
Welzel J; Wolff HH; Gehring W
J Cosmet Dermatol; 2022 Mar; 21(3):1057-1064. PubMed ID: 33955628
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial.
Shin HS; Won CH; Lee SH; Kwon OS; Kim KH; Eun HC
Am J Clin Dermatol; 2007; 8(5):285-90. PubMed ID: 17902730
[TBL] [Abstract][Full Text] [Related]
15. Contrast enhanced phototrichogram pinpoints scalp hair changes in androgen sensitive areas of male androgenetic alopecia.
Leroy T; Van Neste D
Skin Res Technol; 2002 May; 8(2):106-11. PubMed ID: 12060475
[TBL] [Abstract][Full Text] [Related]
16. HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled, multicentre trial.
Leavitt M; Charles G; Heyman E; Michaels D
Clin Drug Investig; 2009; 29(5):283-92. PubMed ID: 19366270
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.
Suchonwanit P; Srisuwanwattana P; Chalermroj N; Khunkhet S
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2257-2263. PubMed ID: 29972712
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: A randomized controlled trial.
Shapiro J; Ho A; Sukhdeo K; Yin L; Lo Sicco K
J Am Acad Dermatol; 2020 Nov; 83(5):1298-1303. PubMed ID: 32653577
[TBL] [Abstract][Full Text] [Related]
19. Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies.
Gassmueller J; Hoffmann R; Webster A
Br J Dermatol; 2008 Jan; 158(1):109-15. PubMed ID: 17986309
[TBL] [Abstract][Full Text] [Related]
20. Low-level light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device-controlled multicenter trial.
Kim H; Choi JW; Kim JY; Shin JW; Lee SJ; Huh CH
Dermatol Surg; 2013 Aug; 39(8):1177-83. PubMed ID: 23551662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
